OakChart

Alamar Biosciences Inc

ALMRHealthcare·Medical Devices·USA·Mid·NASD·Nov 11 • 9:56 AM ET

31.94+0.44 (1.40%)
2026-11-11 15:57 CET
Market cap
2,188.67 USD m
Revenue, TTM
33.55 USD m
Net income, TTM
-13.34 USD m
Free cash flow, TTM
-15.20 USD m
EPS diluted, TTM
-0.19
P/E
-
Compare

Price

ALMR against its 20 and 50-day averages
2050beat
20.0025.0030.0035.0040.001.1M2.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALMRclose 31.9420-day 29.8550-day 30.2331.94

19.4% under 39.61 on 6 Oct 2026. Last 15 sessions, 39.6% high to low

Profile

ALMR
52-week range, 63% of the way up
18.8439.61

Alamar Biosciences, Inc. engages in developing a proteomic liquid biopsy platform and sells instruments, consumables & services for the early detection of diseases. Its products include ARGO HT system, NULISA assays for Immunology, neurology & oncology, NULISAqpcr custom assay development, technology access program and Alamar analysis solutions. The company was founded by Yuling Luo, Yiyuan Yin and Steve Chen in May 2018 and is headquartered in Fremont, CA.

IndexRUT
Employees222
IPOApr 17, 2026
ATR, 14d2.52
Rel volume2.75
Short float6.25%
Insider own48.36%
Inst own25.24%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.22B
Enterprise Value2.04B
Income-
Sales-
Book/sh4.37
Cash/sh3.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees222
IPOApr 17, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B7.31
P/C9.79
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.87
Current Ratio9.49
Debt/Eq0.14
LT Debt/Eq0.13
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-0.83
EPS next Q-0.26
EPS this Y-467.62%
EPS next Y30.37%
EPS next 5Y-26.24%
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-89.63%
Sales Q/Q107.55%
EarningsNov 03 AMC
EPS/Sales Surpr.5.71% 11.01%

Ownership

Insider Own48.36%
Insider Trans-4.27%
Inst Own25.24%
Inst Trans38.43%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.99%
SMA505.66%
SMA20017.97%
Trades-

Technical

Shs Outstand69.47M
Shs Float35.88M
Short Float6.25%
Short Ratio3.68
Short Interest2.24M
52W High39.61 -19.36%
52W Low18.84 69.49%
Volatility9.36% 8.92%
ATR (14)2.52
RSI (14)54.60
Beta-
Rel Volume2.75
Avg Volume610.20K
Volume190,274

Performance

Perf Week16.61%
Perf Month35.80%
Perf Quarter-2.98%
Perf Half Y38.81%
Perf YTD41.33%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.40
Target Price37.00
Prev Close31.50
Price31.94
Change %1.40%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
May 12, 2026InitiatedTTD CowenBuy$30-6.1%
May 12, 2026InitiatedSStifelBuy$28-12.3%
May 12, 2026InitiatedLLeerink PartnersOutperform$35+9.6%
May 12, 2026InitiatedJJP MorganOverweight$30-6.1%
May 12, 2026InitiatedBBofA SecuritiesNeutral$27-15.5%

Peers

Mkt cap
TickerCompanyMkt cap
QTRXQuanterix Corp158.58M
ILMNIllumina Inc32.99B
TXG10x Genomics Inc8.47B
QSIQuantum-Si Incorporated293.36M
TECHBio-Techne Corp11.44B
SEERSeer Inc91.37M
BRKRBruker Corp9.60B
TMOThermo Fisher Scientific Inc266.64B
LABStandard BioTools Inc276.75M
NAUTNautilus Biotechnology Inc312.70M

Insider trading

latest 14 of 19
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Qiming Corporate GP VI, Ltd.10% OwnerNov 03 '26Sale29.89111,3133,327,146158,967Nov 05 04:10 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 30 '26Sale30.38143,7064,365,384161,679Nov 03 04:15 PM
Qiming Corporate GP VI, Ltd.10% OwnerNov 02 '26Sale29.8443,9301,311,029160,913Nov 03 04:15 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 28 '26Sale32.77100,8373,303,983164,191Oct 29 04:09 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 27 '26Sale31.3984,8942,664,905165,953Oct 29 04:09 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 23 '26Sale30.59147,9344,525,068169,753Oct 27 04:10 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 26 '26Sale30.52132,5244,044,691167,438Oct 27 04:10 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 21 '26Sale30.31208,8156,328,758174,677Oct 23 07:35 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 22 '26Sale29.33133,8113,924,337172,338Oct 23 07:35 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 20 '26Sale27.89142,0043,961,103178,326Oct 21 07:15 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 19 '26Sale26.3475,5081,988,881180,808Oct 21 07:15 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 15 '26Sale27.73173,5374,812,446182,130Oct 19 04:30 PM
Qiming Corporate GP VI, Ltd.10% OwnerOct 16 '26Sale27.021363,675182,128Oct 19 04:30 PM
Qiming Venture Partners VIII-HAffiliateOct 14 '26Proposed Sale23.52435,46810,242,000Oct 14 08:33 PM

Held by

AUM
TickerCompanyAUM
ARKGARK Genomic Revolution ETFAUM: 1.97B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
LFSCF/m Emerald Life Sciences Innovation ETFAUM: 130.02M
IWNiShares Russell 2000 Value ETFAUM: 14.10B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B

News

latest 14 of 62
  • Alamar Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.36%
  • Alamar: Q3 Earnings Snapshot (Associated Press)
  • Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance (GlobeNewswire)
  • Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine (GlobeNewswire)
  • UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study (GlobeNewswire) -5.42%
  • Loading…
  • Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study (GlobeNewswire)
  • Emory Researchers Identify Blood Protein Signature That Detects ALS With 98% Accuracy Using Alamar Technology (GlobeNewswire) +7.42%
  • Alamar Biosciences Faces A Higher Bar On Growth As Bearish Sentiment Builds (Earnings Whispers) +5.07%
  • Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026 (GlobeNewswire) -6.70%
  • Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team (GlobeNewswire) +10.97% -15.39%
  • Lancet Neurology Study Using Alamar Biosciences' Technology Reveals Divergent Biological Responses to Alzheimer's Treatment (GlobeNewswire)
  • Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
  • Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ... (GuruFocus.com) +30.65%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.190-0.202-0.19033.5530.225
2026Q22026-08-10-0.220-0.308-0.19029.4025.865
2026Q12026-06-03-1.710-1.710-0.30826.0226.014
2025Q42026-02-25-0.110--0.25025.01--
2026Q4---0.260--33.215
2027Q1---0.270--36.113
2027Q2---0.243--40.743
2027Q3---0.230--44.833
2027Q4---0.220--49.342

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-0.480--0.66574.15-
2026FY--1.192--122.21
2027FY--0.830--167.84
2028FY--0.423--225.93
2029FY-0.310--299.53
2030FY-0.520--410.3

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0452033.2132.9933.80
2026Q4S2026-11-0350032.9132.2033.59
2026Q4S2026-10-2550032.9132.2033.59
2026Q4S2026-10-1353232.9132.2033.59
2026Q4S2026-08-1153232.8832.2033.59
2026Q4S2026-07-1550032.3530.7434.30
2026Q4S2026-06-0350032.2930.7434.30
2026Q4S2026-05-1250032.2930.7434.30
2026Q4S2026-05-1140032.6831.4034.30
2026Q4R2026-11-04303-0.28-0.30-0.27
2026Q4R2026-11-03310-0.21-0.24-0.18
2026Q4R2026-10-25310-0.21-0.24-0.18
2026Q4R2026-10-13311-0.21-0.24-0.18
2026Q4R2026-08-11302-0.21-0.24-0.18

Estimate history

EPS, annual-0.708-0.448
Period20242025
EPS, quarterly-0.111-0.101-0.115-0.308-0.19-0.192
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual25.14274.211
Period20242025
Sales, quarterly13.09116.16219.91326.03529.42733.545
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual66.52166.52169.467
Period20242025MRQ
Shares, quarterly69.31169.31169.31169.31169.38869.467
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue33.5574.2125.14
Cost of Goods Sold Incl. D&A12.9032.5116.54
Gross Profit20.6441.708.61
Selling, General and Administrative Excl. Other35.7873.0458.17
Research and Development16.1737.4739.23
Other Operating Expense0.000.000.00
Operating Income-15.14-31.33-49.57
Interest Expense0.150.402.08
Unusual Expense0.000.000.00
Net Income Before Taxes-13.25-29.15-47.06
Income Taxes0.090.670.01
Consolidated Net Income-13.34-29.82-47.07
Net Income From Continuing Operations-13.34-29.82-47.07
Net Income-13.34-29.82-47.07
EPS (Recurring)-0.19-0.45-0.71
EPS (Basic, Before Extraordinaries)-0.19-0.45-0.71
EPS (Diluted)-0.19-0.45-0.71
EBITDA-13.71-27.47-46.37
Non-Operating Income (Expense)2.042.584.59
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense3.092.270.69
Gross Margin-56.2034.23
Operating Margin--42.22-197.15
Net Margin--40.18-187.23
Shares Outstanding69.4766.5266.52
Market Capitalization2,188.672,188.67-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Total Revenue33.5529.4326.0419.9116.1613.09
Cost of Goods Sold Incl. D&A12.9011.7111.588.027.586.70
Gross Profit20.6417.7214.4611.908.586.39
Selling, General and Administrative Excl. Other35.7831.2526.8019.7816.5014.94
Research and Development16.1713.8213.0210.218.898.30
Other Operating Expense0.000.000.000.000.000.00
Operating Income-15.14-13.53-12.35-7.88-7.92-8.55
Interest Expense0.150.220.220.090.050.05
Unusual Expense0.001.388.590.000.000.00
Net Income Before Taxes-13.25-13.29-20.86-7.56-7.02-7.66
Income Taxes0.09-0.090.460.440.000.00
Consolidated Net Income-13.34-13.20-21.32-8.00-7.02-7.66
Net Income From Continuing Operations-13.34-13.20-21.32-8.00-7.02-7.66
Net Income-13.34-13.20-21.32-8.00-7.02-7.66
EPS (Recurring)-0.19-0.18-0.22-0.12-0.10-0.11
EPS (Basic, Before Extraordinaries)-0.19-0.19-0.31-0.12-0.10-0.11
EPS (Diluted)-0.19-0.19-0.31-0.12-0.10-0.11
EBITDA-13.71-12.40-11.18-6.90-7.00-7.67
Non-Operating Income (Expense)2.041.840.300.410.940.94
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense3.092.591.160.560.540.49
Gross Margin61.5460.2155.5359.7453.0948.80
Operating Margin-45.13-45.98-47.42-39.60-49.00-65.33
Net Margin-39.77-44.85-81.91-40.18-43.45-58.51
Shares Outstanding69.4769.3969.3169.3169.3169.31
Market Capitalization2,188.671,877.641,924.77---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments30.0079.36
Short Term Receivables12.757.06
Inventories38.4814.41
Other Current Assets13.475.87
Total Current Assets94.70106.70
Net Property, Plant & Equipment36.6335.10
Total Investments and Advances4.914.91
Intangible Assets1.992.04
Other Assets1.760.77
Total Assets139.99149.51
Short Term Debt Incl. Current Port. of LT Debt2.101.91
Accounts Payable5.876.19
Other Current Liabilities15.768.49
Total Current Liabilities23.7316.59
Long Term Debt274.37266.19
Provision for Risks Charges0.250.14
Other Liabilities0.600.00
Total Liabilities298.95282.92
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value0.000.00
Common Equity-158.95-133.41
Total Shareholders Equity-158.95-133.41
Accumulated Minority Interest0.000.00
Total Equity-158.95-133.41
Total Liabilities & Stockholders Equity139.99149.51
Book Value Per Share-2.39-2.01
Tangible Book Value Per Share-2.42-2.04
Full-Time Employees222-
Price to Book Ratio7.21-
Return on Assets-20.60-
Return on Invested Capital-25.84-35.45
Quick Ratio2.375.56
Current Ratio3.996.43

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-13.34-29.82-47.07
Depreciation1.423.863.19
Other Funds (Non Cash)4.244.920.65
Funds from Operations-7.68-21.04-43.23
Extraordinary Item0.000.000.00
Changes in Working Capital-7.05-32.57-11.99
Cash from Operating Activities-14.73-53.61-55.21
Capital Expenditures-0.64-6.38-3.39
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments12.3852.56-50.55
Purchase of Investments-7.62-4.94-92.53
Sale Or Maturity of Investments20.0057.5041.98
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities11.7446.18-53.93
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock0.270.94128.42
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock0.270.94128.42
Proceedsfrom Stock Options0.00-0.56127.48
Issuance or Reduction of Debt, Net-10.129.90-15.00
Change in Long Term Debt-10.129.90-15.00
Issuance of Long Term Debt0.009.900.00
Reduction of Long Term Debt-10.120.00-15.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities-9.8510.84113.42
Exchange Rate Effect0.06-0.17-0.00
Net Change in Cash-12.783.234.27
Free Cash Flow-15.20-58.98-58.16
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments226.59250.0564.59---
Short Term Receivables21.6120.3419.52---
Inventories54.1345.4139.93---
Other Current Assets15.3615.5812.53---
Total Current Assets317.69331.38136.57---
Net Property, Plant & Equipment51.4849.1636.14---
Total Investments and Advances4.916.254.91---
Intangible Assets1.441.601.84---
Other Assets2.512.586.99---
Total Assets378.03390.98186.45---
Short Term Debt Incl. Current Port. of LT Debt2.482.281.60---
Accounts Payable16.5513.795.63---
Other Current Liabilities14.4511.8916.81---
Total Current Liabilities33.4827.9624.05---
Long Term Debt39.8749.13338.95---
Provision for Risks Charges0.000.000.00---
Other Liabilities0.971.031.53---
Total Liabilities74.3278.12364.52---
Non-Equity Reserves0.000.000.00---
Preferred Stock - Carrying Value0.000.000.00---
Common Equity303.70312.86-178.07---
Total Shareholders Equity303.70312.86-178.07---
Accumulated Minority Interest0.000.000.00---
Total Equity303.70312.86-178.07---
Total Liabilities & Stockholders Equity378.03390.98186.45---
Book Value Per Share4.374.51-2.57---
Tangible Book Value Per Share4.354.49-2.60---
Full-Time Employees--250---
Price to Book Ratio7.21-10.54-10.81---
Return on Invested Capital-3.88-3.65-13.26---
Quick Ratio7.8710.234.02---
Current Ratio9.4911.855.68---

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-13.34-13.20-21.32-8.00-7.02-7.66
Depreciation1.421.131.170.980.920.89
Other Funds (Non Cash)4.245.5211.201.770.760.77
Funds from Operations-7.68-6.54-8.96-5.25-5.34-6.01
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-7.05-4.78-11.39-8.89-6.54-7.06
Cash from Operating Activities-14.73-11.32-20.35-14.14-11.88-13.07
Capital Expenditures-0.64-3.75-0.78-1.33-1.11-0.98
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments12.38-117.050.0015.5219.0618.00
Purchase of Investments-7.62-117.050.00-2.48-4.940.00
Sale Or Maturity of Investments20.000.000.0018.0024.0018.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities11.74-120.80-0.7814.1917.9517.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.27201.84-0.410.460.160.24
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.27201.84-0.410.460.160.24
Proceedsfrom Stock Options0.00200.61-2.220.000.000.00
Issuance or Reduction of Debt, Net-10.120.0056.189.940.000.00
Change in Long Term Debt-10.120.0056.189.940.000.00
Issuance of Long Term Debt0.000.0056.5010.000.000.00
Reduction of Long Term Debt-10.120.00-0.32-0.060.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-9.85201.8455.7610.400.160.24
Exchange Rate Effect0.060.01-0.05-0.470.340.13
Net Change in Cash-12.7869.7334.589.986.564.33
Free Cash Flow-15.20-14.96-20.95-15.36-12.63-13.62

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.25%2.2M35.9M540.50K
2026-10-157.47%2.7M35.8M459.14K
2026-09-307.85%2.8M35.8M363.35K
2026-09-155.92%2.1M35.8M343.56K
2026-08-315.92%2.1M35.9M324.41K
2026-08-145.79%2.1M35.8M313.63K
2026-07-316.25%2.4M38.9M287.21K
2026-07-155.78%2.2M38.9M397.59K
2026-06-307.18%2.8M38.9M416.83K
2026-06-154.83%1.9M38.9M378.50K
2026-05-294.67%1.8M37.9M456.44K
2026-05-154.49%1.7M37.9M538.72K
2026-04-303.17%1.2M36.4M876.48K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-034Statement of changes in beneficial ownership of securities2026-10-30SEC
2026-11-038-KCurrent report2026-10-30SEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-14144Filing for proposed sale of securities under Rule 144.SEC
2026-10-14144Filing for proposed sale of securities under Rule 144.SEC
2026-10-14144Filing for proposed sale of securities under Rule 144.SEC
2026-10-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-163Initial statement of beneficial ownership of securities2026-09-14SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-033Initial statement of beneficial ownership of securities2026-09-01SEC
2026-09-018-KCurrent report2026-08-28SEC
2026-08-13SCHEDULE 13GSEC
2026-08-11SCHEDULE 13GSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-158-KCurrent report2026-07-15SEC
2026-07-07SCHEDULE 13D/ASEC
2026-07-02SCHEDULE 13GSEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-088-KCurrent report2026-05-08SEC
2026-04-23SCHEDULE 13DSEC
2026-04-23SCHEDULE 13DSEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11004.64M2
2026-100039.92M11
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-048.00M200
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Sands Capital Alternatives, LLC6.10%
Samsara BioCapital, LLC3.58%
T. Rowe Price Investment Management, Inc.3.18%
ARK Investment Management LLC1.98%
BRAIDWELL LP1.56%
ALLIANCEBERNSTEIN L.P.1.45%
HHLR ADVISORS, LTD.1.38%
BlackRock, Inc.1.32%
MILLENNIUM MANAGEMENT LLC1.25%
FMR LLC1.20%

Funds

Fund% owned
ARK Genomic Revolution ETF1.38%
ARK Venture Fund0.96%
Columbia Small Cap Growth Fund0.68%
AB Small Cap Growth Portfolio0.64%
T. Rowe Price Small-Cap Stock Fund, Inc.0.51%
iShares Russell 2000 ETF0.46%
SmallCap Growth Fund I0.46%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.46%
Select Health Care Portfolio0.43%
Emerald Growth Fund0.40%

OakChart. ALMR. Cached 15 minutes.